Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 May;88(5):708-13.
doi: 10.1136/bjo.2003.032250.

Cannabinoids and glaucoma

I Tomida  1 , R G Pertwee, A Azuara-Blanco
Affiliations
Review

Cannabinoids and glaucoma

I Tomida et al. Br J Ophthalmol. 2004 May.

Abstract

Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse therapeutic possibilities, new and better treatments for glaucoma are highly desirable. Cannabinoids effectively lower the intraocular pressure (IOP) and have neuroprotective actions. Thus, they could potentially be useful in the treatment of glaucoma. The purpose of this article is to provide the reader with an overview of the latest achievements in research into the potential use of cannabinoids for glaucoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Photograph of the Cannabis sativa plant (provided by GW Pharmaceuticals, Wiltshire, UK)
Figure 2
Figure 2
Chemical structure of typical classic cannabinoids Δ9-tetrahydrocannabinol, cannabinol, and HU-211.
Figure 3
Figure 3
Chemical structure of nabilone, cannabidiol, and cannabigerol.
Figure 4
Figure 4
Chemical structure of endogenous cannabinoids anandamide (AEA), 2-arachidonoyl glycerol (2-AG), and 2-arachidonyl glyceryl ether (noladin).
See this image and copyright information in PMC

References

    1. Frankhauser M. Cannabis in der westlichen Welt. In: Grotenhermen F, ed. Cannabis und cannabinoide. 1st ed. Berlin: Verl Hans Huber, 2001:57–71.
    1. Chalsma AL, Boyum D. Marijuana situation assesment. Washington DC: Office of National Drug Control Policy, 1994.
    1. Schwab IR, Husted R, Liegner JT, et al. Complementary therapy assessment: Marijuana in the treatment of Glaucoma. San Francisco: American Academy of Ophthalmology, Complementary Therapy Task Force, 1999.
    1. Grotenhermen F. Die Wirkungen von Cannabis und der Cannabinoide. In: Grotenhermen F, ed. Cannabis und cannabinoide, 1st ed. Berlin: Verl Hans Huber, 2001:75–86.
    1. ElSohly MA. Chemical constituents of cannabis. In: Grotenhermen F, Russo E, eds. Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential. New York: Haworth Press, 2002:27–36.